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Tumor hypoxia, a common feature occurring in nearly all human solid tumors is a major contributing factor for failures of 
anticancer therapies. Because ionizing radiation depends heavily on the presence of molecular oxygen to produce cytotoxic effect, 
the negative impact of tumor hypoxia had long been recognized. In this review, we will highlight some of the past attempts to 
overcome tumor hypoxia including hypoxic radiosensitizers and hypoxia-selective cytotoxin. Although they were (still are) a very 
clever idea, they lacked clinical efficacy largely because of ‘reoxygenation’ phenomenon occurring in the conventional low dose 
hyperfractionation radiotherapy prevented proper activation of these compounds. Recent meta-analysis and imaging studies do 
however indicate that there may be a significant clinical benefit in lowering the locoregional failures by using these compounds. 
Latest technological advancement in radiotherapy has allowed to deliver high doses of radiation conformally to the tumor volume. 
Although this technology has brought superb clinical responses for many types of cancer, recent modeling studies have predicted 
that tumor hypoxia is even more serious because ‘reoxygenation’ is low thereby leaving a large portion of hypoxic tumor cells 
behind. Wouldn’t it be then reasonable to combine hypoxic radiosensitizers and/or hypoxia-selective cytotoxin with the latest 
radiotherapy? We will provide some preclinical and clinical evidence to support this idea hoping to revamp an enthusiasm for 
hypoxic radiosensitizers or hypoxia-selective cytotoxins as an adjunct therapy for radiotherapy.
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Introduction 
Tumor hypoxia is a common feature in many, if not all, human 
and animal solid tumors, which can occur by two mechanisms: 
diffusion-limited chronic hypoxia, proposed by Thomlinson 
and Gray [1] more than 50 years ago where they observed 
uniform bands of necrotic cancer cells approximately 100–150 
μm distant away from blood vessels in human tumors and 
perfusion-limited acute hypoxia proposed by Brown [2] in 
1970’s, which is caused by temporary obstruction or variable 
blood flow in tumor vessels (Fig. 1). By utilizing the gold-
standard Eppendorf probe [3], the partial pressure for oxygen 
has been shown to be much lower in many types of solid 
tumors compared to that of the adjacent normal tissues [4]. 
It is important to note that there is no linear relationship 
between tumor size and the extent of hypoxia. A preclinical 
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study in human colorectal adenocarcinoma xenografts has 
reported that small tumors of less than 1 mm in diameter are 
already being extensively hypoxic and poorly perfused [5].
It has been extensively demonstrated that tumor hypoxia 
is a major contributing factor for the failure of many 
anticancer therapies such as surgery [6], chemotherapy 
[7], and radiotherapy [4]. Tumor hypoxia may also interfere 
with the efficacy of the latest anticancer immunotherapy. 
Many functions including differentiation, maturation, and 
proliferation of various populations of immune cells are 
known to be negatively affected by hypoxic conditions [8]. 
Furthermore, it is recently reported that the expression of 
programmed death-ligand 1 (PD-L1), the major inhibitory 
ligand towards cytotoxic T cells by binding to its cognate 
receptor PD-1 [9] is regulated by hypoxia-inducible factor-1 
(HIF-1) [10], a master transcription factor well known to be 
stabilized in hypoxic cancer cells activating various pathways 
including angiogenesis, glycolytic metabolism, and metastasis 
[11]. 
Hypoxia is a direct and negative impact factor for 
radiotherapy because the molecular oxygen O2 is absolutely 
necessary to chemically fix DNA free radicals produced by 
ionizing radiation [4]. In the absence of O2, DNA radicals are 
repaired by abstracting hydrogen from sulfhydryl (SH) group 
present in protein [4]. It has been reported that three times 
higher ionizing radiation dose is required to kill hypoxic cancer 
cells compared to well-oxygenated cells in order to achieve the 
equivalent level of cell kill [4]. Because of this negative effect 
exerted by hypoxia on radiotherapy outcome, much attempts 
had previously been made to overcome tumor hypoxia. In this 
review, we will highlight some of such attempts and discuss 
future perspectives of tumor hypoxia for radiotherapy.
Past Attempts with Hypoxic 
Radiosensitizers
One of the earliest attempts to overcome radioresistance 
mediated by hypoxic tumor cells was to increase oxygen levels 
in the blood stream by making patients breathe 100% oxygen 
at 3 atmosphere pressure [12]. However, clinical results were 
mixed and the reason was suggested because this strategy was 
ineffective in controlling acutely hypoxic cells [13]. In some 
cases, the use of carbogen (95% O2/5% CO2) has demonstrated 
a greater benefit than 100% oxygen in increasing oxygen levels 
in the blood because of vasodilation effect exerted by CO2 
[14]. Other approaches were the use of nicotinamide, an agent 
to increase tumor blood flow [15], artificial blood substitutes 
carrying increased levels of oxygen such as perfluorocarbons 
[16], and hyperthermia [17] although none of these treatments 
were proven to be clinically effective.
In 1960’s Adams and Cooke [18 ] proposed a clever idea 
that electron-affinic chemical drugs may act like O2, a potent 
radiosensitizer. Radiosensitizer would accept thereby react 
with an electron (Fig. 2A) such as DNA radical produced by 
ionizing radiation. Radiosensitizers would exert their hypoxic 
selective mode of action because the chemical reduction 
would not occur in the presence of O2. O2 either strongly 
back-oxidizes this reductive chemical reaction (Fig. 2A) or 
reacts with DNA radical faster than radiosensitizers would. 
However, unlike O2, these agents are not being metabolized 
by cells through which they penetrate thus able to diffuse 
beyond the oxygen diffusion distance [19]. With misonidazole 
and metronidazole being the prototype members of 
nitroimidazole class of hypoxic radiosensitizers (other classes 
of radiosensitizers are reviewed elsewhere by Ahn and Brown 
[20]) (Fig. 2B), many clinical studies were conducted but 
revealed rather disappointing results. They had very little 
efficacy in improving the clinical response while there was a 
high incidence of peripheral neuropathy when multiple doses 
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Fig. 2. Hypoxic radiosensitizers. (A) Hypoxic selective mechanism 
of action for nitroimidazole class (R-NO2) of radiosensitizers. (B) 
Chemical structure of metronidazole and misonidazole.
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Fig. 1. A diagram demonstrating chronic hypoxia (left) and acute 
hypoxia (right).
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were given [21]. Why multiple doses? Repeated administration 
of radiosensitizers was required because it needed to be given 
immediately prior to each fraction of 2 Gy, 5 fractions per 
week for 4–8 weeks of the conventional ‘fractionated’ schedule 
of radiotherapy. Therefore attempts to increase hydrophilicity 
thereby lowering peripheral neuropathy of misonidazole 
had been made and this lead to the development of analogs 
including etanidazole [22], pimonidazole [23], and nimorazole 
[19]. Although etanidazole was shown to be significantly less 
toxic in mice [22] as with misonidazole it caused peripheral 
neuropathy upon chronic administration [24] and it lacked a 
significant clinical efficacy in a randomized phase III trial in 
head and neck cancer patients treated with radiotherapy [25]. 
Pimonidazole demonstrated approximately 10-fold increase in 
radiosensitization potency in vitro compared to misonidazole 
[26] although its dose limiting toxicity was still associated with 
some immediate effects involving the central nervous system 
[23]. As with other radiosensitizers, pimonidazole was not 
effective as an adjunct to radiotherapy and one of the reasons 
had been suggested to be due to an incomplete randomization 
of patients between control and test arms such that there 
were unexpectedly good results obtained in the control 
arm of the trial [27]. Despite all these disappointing clinical 
results above, a recent meta-analysis performed in 4,805 
head and neck cancer patients in 32 randomized clinical trials 
revealed that hypoxic modifications such as oxygen breathing, 
the use of nicotinamide or nitroimidazoles (misonidazole, 
metronidazole, and etanidazole) offered a significant clinical 
benefit when loco-regional control and overall survival were 
used as the endpoint [28]. With the exhausted enthusiasm 
for hypoxic radiosensitizers, misonidazole is currently being 
utilized in the clinic as a positron-emission tomography (PET) 
[29] probe detecting tumor hypoxia [30] and pimonidazole, 
also known as ‘hypoxyprobe’ is being used to detect the tissue 
hypoxia in the pre-clinical setting [31]. Doranidazole is the 
latest member of this class of hypoxic radiosensitizers and has 
recently shown a significant improvement in the long-term 
survival of unresectable pancreatic cancer patients when given 
with 25 Gy postoperative radiotherapy [32].
In the mid 80’s, Brown [33] developed a novel agent named 
tirapazamine that can selectively kill hypoxic cells thereby 
turning tumor hypoxia from a problem to a selective treatment 
advantage (Fig. 3). This so-called ‘hypoxia-selective cytotoxin’ 
tirapazamine demonstrated hypoxic cytotoxicity ratio of 50–
200 in murine and human cancer cell lines although in vivo 
hypoxic cytotoxicity was somewhat lower than that in vitro 
[34]. Tirapazamine had been extensively tested in combination 
with radiation or cisplatin in many preclinical and clinical 
studies [34]. With the dose-limiting toxicities of reversible 
muscle cramping, nausea, and vomiting, many phase I and II 
trials demonstrated promising results in patients particularly 
with the head and neck or the lung cancers [34]. However, 
despite promising earlier clinical results, most of the phase III 
clinical trials results turned out that tirapazamine did not add 
a significant improvement in prolonging the overall survival 
for patients treated with chemotherapy [34] or chemoradiation 
[29], likely to be due to the lack of information on the extent 
of patients’ tumor hypoxia upon patient selection and 
randomization of the trial.
Hypoxia Imaging–Important Lessons  
We Have Recently Learned from 18F-MISO 
and Tirapazamine
Although misonidazole lacked cl inical  eff icacy as a 
radiosensitizer, 18F-misonidazole (18F-MISO) is currently being 
utilized in the clinic as a PET probe imaging tumor hypoxia [35]. 
With recent 18F-MISO PET imaging studies, we have acquired 
some very valuable information.
First, Trans-Tasman Radiation Therapy Oncology Group 
(RTOG) 98.02 study in advanced squamous cell carcinoma 
of the head and neck patients has demonstrated that 
tirapazamine, which had otherwise failed in phase III clinical 
trials above [29] could be dramatically effective in lowering the 
locoregional failure if patients were selected based on tumor 
hypoxia by 18F-MISO PET scans in prior [36]. In that study, only 
one of 19 head and neck cancer patients had recurrence when 
tirapazamine was given in combination with chemoradiation 
whereas 8 out of 13 patients recurred if they received 
5-fluorouracil in place of tirapazamine [36] (Fig. 4). These 
results thus indicate that all those clever ideas developed in 
1970’s and 1980’s would work well if we could better identify 
patients with significant hypoxic fractions being present in 
their tumors. 
Second, 18F-MISO PET imaging has shown that tumor 
hypoxia can dramatically change over time, as early as a few 
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Fig. 3. Hypoxic selective mechanism of action for tirapazamine.
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hours up to days [37]. Although there had been some attempts 
to measure the dynamics and kinetics of changes in tumor 
hypoxia, it was largely concluded that it occurred rather 
subtly and unpredictably, and that it frequently associated 
with immature blood vessels [37]. Due to the unpredictable 
nature, changes in tumor hypoxia can significantly complicate 
the latest radiotherapy technology, for example intensity-
modulated radiotherapy (IMRT; see below ‘Recent advances 
in radiotherapy technology’) dose-painting technology where 
additional boost dose of irradiation can be given to hypoxic 
Locoregional Failure by Treatment Arm and Hypoxia
Hypoxia Status
Treatment
Chemoboost TPZ / CIS
No. of 
Locoregional 
Failures
No. of 
Patients
No. of 
Locoregional 
Failures
No. of 
Patients
Nonhypoxic 1 10 2 3
Hypoxia in primary tumor 
  and / or nodes
8 13 1 19
RT: 70 Gy in 35 fractions over 7 weeks
•  CIS (50 mg/m2) + RT (week 
6&7)
•  Cont. 5-FU (360 mg/m2/d) 
d1-5 in week 6&7)
•  TPZ (290 mg/m2) + CIS (50 
mg/m2) + RT (week 6&7)
•  TPZ (160 mg/m2) week 
2&3
Fig. 4.  Locoregional failure by treatment 
arm and hypoxia. Tirapazamine offers 
a significant benefit lowering the 
locoregional failures in head and neck 
cancer patients with hypoxia (red box). 
TPZ/CIS, tirapazamine/cisplatin; RT, 
radiotherapy. Modified from Rischin et 
al. [36] with permission of the American 
Society of Clinical Oncology.
Fig. 5. Tumor hypoxia is dynamically changing. (A) A positron emission tomography-computed tomography (PET-CT) image (left) and 
intensity-modulated radiotherapy (IMRT) treatment (right) for a patient whom do not demonstrate a significant change in the tumor 
hypoxia as examined by two consecutive 18F-misonidazole (18F-MISO) images (left). (B) A significant change in the location of tumor 
hypoxia is noted in this patient between 1st (red area) and 2nd (green area) images of F-MISO PET (left). Upon IMRT treatment (right), 
newly hypoxic areas (green) would receive the dose not enough to kill hypoxic cells while those tumor areas that are no longer hypoxic 
would experience overdose of irradiation. Adapted from Lin et al. [38] with permission of Elsevier. 
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regions of tumors. For example, Lin et al. [38] have reported 
that some patients whose tumor hypoxia varies significantly 
from day to day would not benefit such dose-painting 
radiotherapy because ‘newly hypoxic’ regions of tumors 
would receive the dose that is not high enough to kill hypoxia 
while ‘now no-longer’ hypoxic regions would be treated with 
unnecessarily high dose of irradiation (Fig. 5).
Recent Advances in Radiotherapy 
Technologies
The ways to deliver radiotherapy have been drastically changed 
over the last decades. Previously, conventional radiotherapy 
had been consisted of relatively small doses (1.2–3 Gy/
fraction) daily fraction over weeks or months based on a small 
survival advantage of the normal tissues over the tumors [39]. 
Importantly, this treatment regimen has led to ‘reoxygenation’ 
phenomenon, in which surviving hypoxic tumor cells at a given 
dose become oxygenated by the time of the next fractionation 
treatment [40], which has turned out to be one way to 
effectively kill hypoxic tumor cells. Much of radiobiological 
work with this fractionated irradiation has taught us that the 
normal tissue toxicity occurring by fractionated irradiation has 
been shown to be dependent upon several factors including 
the fraction size, tissue type, and total doses of radiation [39]. 
Based on this understanding, some of altered fractionation 
schemes were further developed: hyperfractionation of 
smaller fraction doses, increased numbers of fractions, and 
interfractionation intervals by at least 6 hours (because 
sublethal damage repair has shown to occur within 6 hours); 
or accelerated fractionation where the overall treatment time 
being shortened in order to reduce accelerated repopulation of 
tumor cells [39]. These modifications in fractionated irradiation 
have shown to improve the local control rates while the late 
normal tissue toxicity not being significantly different [41]. 
Recent technological advancement has allowed us to deliver 
single large fraction of 15–20 Gy precisely to the tumor-
bearing volume, known as stereotactic radiosurgery (SRS) 
for cranial lesions and stereotactic body radiotherapy (SBRT) 
for other extracranial sites [39]. Use of such technologies 
has significantly improved the clinical response: for example 
recent results from RTOG 0236 protocol in non-operable early-
stage lung cancer patients treated with 3 fractions of 20 Gy/
fraction SBRT have shown 3 year local control and survival to 
be 98% and 56%, respectively, the results being comparable to 
surgery [42]. Computer-controlled beam shapes with multileaf 
collimators and intensity modification by using a wedge-
shaped compensating filter have led to IMRT allowing highly 
conformal distributions of high doses of radiation in target 
volumes while maintaining the low levels of radiation to the 
surrounding normal tissues [39]. 
Tumor Hypoxia with SBRT—Back to  
Square One?
Without a doubt, the recent advancement in radiotherapy 
technology has brought superior clinical responses in 
numerous cancer patients. However has this technology 
overcome the problem of tumor hypoxia? A recent modeling 
study by Carlson et al. [43] suggested that assuming daily 
fractionation and full reoxygenation between fractions, tumor 
hypoxia is actually more serious problem with SBRT. Tumor 
cell survival can increased up to 100-fold as we choose ‘less 
number’ of fractions and ‘at higher dose’ per fraction (‘A’ in 
Fig. 6), which may be equivalent to current SBRT. In addition, 
an increase in hypoxic fraction from 10% to 30% has modeled 
to reflect nearly 10 times further resistance of tumor cells at 
fhyp = 0.2
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Fully oxygenated cells
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Fig. 6. Total surviving clones as a function of dose per fraction 
assuming daily fractionation and full reoxygenation between 
fractions. A: For tumors with 10% hypoxia (fhyp = 0.1; red line) 
there is more than 2 logs (100-fold) of cell survival advantage 
(pointed with the orange arrow) as we reduce the number of 
fractionations (as we shift right to left). B: As hypoxic fraction 
increases from 10% (fhyp = 0.1; red line) to 30% (fhyp = 0.3; green 
line), there is additional 1 log (10-fold) of cell survival increase 
(pointed with the black arrow) at 5 fractionation treatment, at 
which the cell survival is already being much higher than that 
by hyperfractionation. Adapted from Carlson et al. [43] with 
permission of Elsevier.
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this high dose hypofractionated regimen [43] (‘B’ in Fig. 6). The 
reason has been suggested largely to be due to a reduction in 
interfractionation reoxygenation associated with this single 
high dose SBRT.
What can we do about it? An obvious way would be 
to deliver the next fraction of SBRT to tumors where the 
tumor reoxygenation would be at its maximum. This may 
even mean ‘personalized’ radiotherapy based on monitoring 
individuals’ changes in tumor hypoxia, which in reality 
would be extremely difficult to do so. In fact, one of current 
dilemma for SBRT is that there are no standardized intervals 
between each hypofractionation. For examples, Timmerman 
et al. [44] prescribed 18 Gy per fraction × 3 fractions within 2 
weeks, while Nagata et al. [45] prescribed 12 Gy per fraction 
× 4 over 5–13 days. In one study 50 Gy was delivered over 
4 consecutive days, meaning 12.5 Gy every day for 4 days 
[46]. Surprisingly all those studies demonstrated good clinical 
outcome despite differences in their fractionation intervals. 
Does it mean that SBRT does not rely on reoxygenation? 
Probably the good clinical response may derive from such 
‘ablative’ doses of ionizing radiation producing tremendous 
of DNA damages in the affected areas. We have recently 
investigated if we can determine changes in tumor hypoxia 
before and after a single high dose of 20 Gy irradiation by 
utilizing various techniques including 18F-MISO PET imaging, 
pimonidazole, and bioluminescence imaging in a mouse tumor 
model [47]. We found that tumor hypoxia did not significantly 
change when examined at 6 hours, 2 days, and 5 days post-
radiation although we interestingly observed that such high 
dose irradiation caused a rapid but transient vascular collapse 
[47]. There are similar attempts currently undergoing in lung 
cancer patients by Kelada et al. [48]. In their preliminary 
study, there was an increase in tumor hypoxia shortly after 
18 Gy measured by 18F-MISO PET imaging although inter- and 
intra-patient variability was too high to firmly conclude their 
findings. 
If inter- and intra-individual tumor hypoxia changes are too 
variable to predict, an easy alternative (at least until we have 
a better technology imaging/monitoring real time changes of 
tumor hypoxia) would be to use radiosensitizers. As a matter 
of fact, radiosensitizers of many preclinical studies of in vivo 
[49,50] and in vitro [51] in earlier days had been tested at 
much higher radiation doses (5–30 Gy), equivalent to today’s 
SBRT and demonstrated that it would work much better with 
high doses of irradiation [51] (Fig. 7). A recent preclinical study 
by Wittenborn and Horsman [52] has demonstrated the proof-
of-concept that TCD50 (radiation dose to cure 50% of tumors) 
can be decreased from 29.7 Gy to 2.5 Gy when 3 × 15 Gy was 
combined with nimorazole 30 minutes prior to each fraction 
(Table 1). Clinical enthusiasm may have been exhausted and 
doomed because of disappointing clinical results with nearly 
all of hypoxic radiosensitizers tested (see above ‘Past attempts 
with hypoxic radiosensitizers’). However, there is a clinical 
study as early as in 1980’s that 9 out of 10 vulvovaginal 
cancer patients achieved the local control when metronidazole 
was given as a radiosensitizer with high-dose radiation [53]. 
A recent clinical study with doranidazole has demonstrated 
a significant improvement in 3-year survival in advanced 
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Fig. 7. Survival curves of Chinese 
hamster  ovary (CHO) ce l ls 
irradiated under oxic (O2), hypoxic 
(N2) ,  or hypoxic conditions 
in the presence of 1.5 mM 
misonidazole (red line) by 270 
kVp X-ray irradiation at (A) high 
or (B) low dose range. Note that 
sensitization enhancement ratio 
(yellow arrows) of misonidazole 
is larger at higher irradiation 
dose range (A). Adapted from 
Palcic et al. [51] with permission 
of publisher.
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pancreatic cancer patients when it was combined with 25 Gy 
intraoperative radiotherapy [32]. These preclinical and clinical 
results thus indicate that hypoxic radiosensitizers or hypoxia-
selective cytotoxins may work well with the latest high dose 
hypofractionation radiotherapy.
Future Perspectives
Because of tumor hypoxia and the normal tissue complication, 
other radiotherapy modalities such as charged particle beam 
radiotherapy of proton or carbon ion are being actively 
developed and utilized to treat cancers world-wide. Compared 
to X-ray, carbon ion offers advantages of superior cell kill and 
a potential to decrease normal tissue toxicity [54]. This is first 
because carbon ion is of high linear energy transfer (LET), it 
does not depend on the oxygen effect for producing cell kill. 
Second, Bragg peak, the extent of energy loss of radiotherapy 
along the penetration depth of tissues as it travels through 
is even optimal with carbon ion therapy among other heavier 
ions–carbon ion has the lowest entry relative biological 
effectiveness (RBE; the ratio in the dose of one type of ionizing 
radiation to another at the same level of biological effects) 
while it demonstrates the maximal RBE in Bragg peak [54]. 
Some of the current limitation of this approach may include 
a limited availability of the facility, high treatment costs, 
and rather short clinical history compared to X-ray ionizing 
radiation. 
In an attempt to take an advantage of the existing clinical 
linear accelerator (LINAC), the newest effort has been 
suggested to use ultra-high dose rate FLASH irradiation [55]. 
The concept was first introduced by Favaudon et al. [56] 
demonstrating that the ultra-high dose rates in the range 
of 40–60 Gy per second resulted in a significantly reduced 
lung toxicity while the local control of tumors was similar 
compared to conventional 17 Gy irradiation. Recently, Schuler 
et al. [55]  are actively tuning and modifying a clinical LINAC 
instrument for electron FLASH offering an easy set up and 
more homogenous dose distribution in tumors than photon-
induced radiotherapy. 
Optical approaches in imaging oxygen tensions and 
delivering oxygen to hypoxic regions of tumors are also being 
actively developed in the preclinical settings. Studies have 
shown that redox ratio of autofluorescence for endogenous 
molecules such as hemoglobin could reflect the oxygen 
tensions in tumors [57] and that this can predict the tumor 
response to irradiation in FaDu head and neck squamous cell 
carcinoma xenograft models in mice [58]. This approach may 
be limited to determination of the oxygen partial pressure 
in blood vessels of tumors not necessarily reflecting those 
within tumors. In this respect, we have recently developed an 
optical oxygen sensor consisting of ruthenium (Ru) complex 
encapsulated in amphiphilic polymer where we can quantify 
the oxygen concentrations based on the ratiometric analyses of 
Ru phosphorescence signal in cancer cells [59]. Dewhirst group 
has also reported a similar approach of boron nanoparticle 
where they have quantified the oxygen in tumors implanted 
underneath in vivo dorsal window chamber [60]. A platinum 
complex of porphyrin complexes has recently demonstrated 
low yet heterogeneous oxygen tension distributions in the 
bone marrow of mice by using phosphorescence lifetime 
imaging [61]. Nanoparticle approaches delivering the molecular 
oxygen to tumors are also very exciting. Prasad et al. [62] have 
shown that albumin-coated manganese oxide nanoparticles 
release the molecular oxygen by H2O2 produced by oxidative 
stress within the tumor microenvironment, which can 
increase the tumor oxygenation up to 45% in tumors leading 
Table 1. Tumor control dose 50 (TCD50) for radiation only or 
radiation combined with hypoxic targeting agent(s) in mice
Treatmenta) TCD50
b) (±95% CI)
Radiation alone (3 × 15 Gy)
Radiation + 1 × nimorazole
Radiation + 3 × nimorazole
Radiation + 1 × nimorazole and  
carbogen
Radiation + 3 × nimorazole and  
carbogen
Radiation + 1 × OXi4503
Radiation + 3 × OXi4503
Radiation + 1 × hyperthermia
Radiation + 3 × hyperthermia
Radiation + 1 × OXi4503 and  
hyperthermia
 29.7 (22.9–38.5)
 20.1 (11.7–34.3)
 2.5 (0.5–13.7)*
 22.9 (16.2–32.4)
 <1.0 (not measurable)
 12.2 (6.0– 24.9)*
 12.1 (7.9–18.6)*
 10.1 (7.0–14.6)*
 8.6 (4.5–16.6)*
 1.9 (0.4–8.5)*
The study showing that tumor control dose 50 (TCD50) can dra-
matically be reduced when high dose (15 Gy) irradiation is com-
bined with hypoxic modifications such as nimorazole (Radiation 
alone), nicotinamide (Radiation + 3 × nimorazole) and carbogen 
(Radiation + 3 × nimorazole and carbogen),  and hyperthermia. 
CI, confidence interval.
a) All modifiers were given with either each 15 Gy fraction (3×) or 
only the last 15 Gy fraction (1×). b)TCD50, clamped top-up radiation 
dose needed to control 50% of the tumors. Data were obtained 
from Figures 1 and 2 [52].  
*indicates a statistically significant difference when compared to 
radiation alone (p < 0.05).
Adapted from Wittenborn and Horsman [52] with permission of 
Taylor & Francis.
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to a significantly increased radiotherapy efficacy in breast 
cancer models in mice. Another interesting approach using 
nanoperfluorocarbon of high oxygen dissolving properties, 
Song et al. [63] have recently demonstrated that these agents 
can pick up the oxygen from the lung and selectively release 
it in tumors only by ultrasound stimulation in hyperoxic 
breathing mice, thereby improving the tumor response to 
radiotherapy and photodynamic therapy [63]. Future studies 
including investigation of pharmacokinetics of these agents 
would be warranted in order to move forward to be applied in 
the clinical setting.
Conclusions
Small doses of hyperfractionation regimen had implemented 
to lower the normal tissue toxicity produced by ionizing 
radiation, which has brought us an important radiobiological 
concept ‘reoxygenation.’ While it turned out to kill hypoxic 
tumor cells efficiently, it paradoxically acted as a major 
disadvantage towards our previous efforts for hypoxic 
radiosensitizers and hypoxia-selective cytotoxins, the two great 
ideas which may have worked so well otherwise. The latest 
technology advancement in radiotherapy using high doses of 
hypofractionation regimen has totally changed the picture 
of cancer treatment and brought superb clinical responses. 
However, recent modeling studies suggest that tumor hypoxia 
would be a significant problem with the latest radiotherapy 
because the interfractionation reoxygenation would be 
minimal. While we do not have reoxygenation phenomenon to 
interfere with hypoxic radiosensitizers and/or hypoxia-selective 
cytotoxins, this may be a perfect time to reconsider combining 
these with the latest radiotherapy technique (Fig. 8). 
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